Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2015
NICE issues draft guidance on evolocumab for lipid disorder
18 November 2015 - NICE has published draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high ...
Posted by Michael Wonder on 18 Nov 2015
Insulin degludec plus liraglutide: again no hint of added benefit in type 2 diabetes says IQWiG
16 November 2015 - The manufacturer presented no relevant data for the assessment of the added benefit of insulin degludec/liraglutide versus ...
Posted by Michael Wonder on 18 Nov 2015
Amgen's cholesterol-buster Repatha turned down for NHS use
18 November 2015 - NICE has turned down Amgen’s Repatha - the world’s first approved PCSK9 inhibitor - as an option ...
Posted by Michael Wonder on 18 Nov 2015
NICE says 'no' to personalised bowel cancer drugs
18 November 2015 - NICE has published interim guidance barring patients with advanced bowel cancer from routine NHS access to Merck ...
Posted by Michael Wonder on 18 Nov 2015
Nivolumab in non-small cell lung cancer: indication of major added benefit for under-75-year-olds
16 November 2015 - According to the findings, there is an indication of major added benefit of nivolumab over the appropriate ...
Posted by Michael Wonder on 18 Nov 2015
Agenda for the 18 November 2015 TC meeting
17 November 2015 - The Transparency Commission wiill consider submission for the following medicines: Jinarc (tolvaptan), Otezla (apremilast), Menotrophine (human ...
Posted by Michael Wonder on 17 Nov 2015
CADTH calls for patient input on a new submission from Eli Lilly for Trulicity
17 November 2015 - CADTH has received notice of a pending submission from Eli LIlly for dulaglutide (Trulicity) for use by ...
Posted by Michael Wonder on 17 Nov 2015
NICE: Kadcyla price still too high
17 November 2015 - Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer combination treatment, Kadcyla (trastuzumab emtansine), ...
Posted by Michael Wonder on 17 Nov 2015
Drug Utilisation Sub Committee outcome statement
13 November 2015 - The outcome statement for the October 2015 Drug Utilisation Sub Committee meeting is now available. ...
Posted by Michael Wonder on 16 Nov 2015
Nivolumab in non small-cell lung cancer: evidence of a considerable additional benefit in patients under 75 years of age according to IQWiG
16 November 2015 - For patients under 75 year of age with a relatively good general condition, there is an ...
Posted by Michael Wonder on 16 Nov 2015
Pembrolizumab has an additional benefit in certain patients with advanced melanoma says IQWiG
16 November 2015 - In treatment experienced patients in whom the use of ipilimumab as the next treatment is suitable, there is ...
Posted by Michael Wonder on 16 Nov 2015
CADTH calls for patient input on a new submission from Bayer for Eylea
16 November 2015 - CADTH received notice of a pending submission from Bayer for Eylea (aflibercept) for use in patients with ...
Posted by Michael Wonder on 16 Nov 2015
Public Summary Documents - PBAC July 2015 meeting
13 November 2015 - Additional Public Summary Documents from the July 2015 PBAC meeting are now available. ...
Posted by Michael Wonder on 13 Nov 2015
SMC announces more forthcoming submissions
12 November 2015 - SMC has announced forthcoming submissions for the following medicines: alirocumab (Praluent), atularen (Translarna), blinatumomab (Blincyto) & ceftolozane with tazobactam (Zerbaxa). ...
Posted by Michael Wonder on 12 Nov 2015
Antihaemophilic factor (recombinant BDD) Fc fusion protein (Eloctate): treatment cost comparison and budget impact analysis
9 November 2015 - CADTH's final science report is now available for the project on antihaemophilic factor (recombinant BDD) Fc fusion ...